PDS Planning Inc lifted its position in CVS Health Co. (NYSE:CVS – Free Report) by 6.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,543 shares of the pharmacy operator’s stock after buying an additional 227 shares during the period. PDS Planning Inc’s holdings in CVS Health were worth $280,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Atticus Wealth Management LLC lifted its position in CVS Health by 149.0% during the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after purchasing an additional 219 shares during the period. Cornerstone Planning Group LLC lifted its position in CVS Health by 111.5% during the third quarter. Cornerstone Planning Group LLC now owns 461 shares of the pharmacy operator’s stock valued at $32,000 after purchasing an additional 243 shares during the period. ZRC Wealth Management LLC lifted its position in CVS Health by 400.0% during the fourth quarter. ZRC Wealth Management LLC now owns 500 shares of the pharmacy operator’s stock valued at $39,000 after purchasing an additional 400 shares during the period. Coston McIsaac & Partners raised its position in CVS Health by 42.6% in the fourth quarter. Coston McIsaac & Partners now owns 539 shares of the pharmacy operator’s stock worth $42,000 after acquiring an additional 161 shares during the period. Finally, Tennessee Valley Asset Management Partners bought a new position in CVS Health in the fourth quarter worth approximately $50,000. Institutional investors own 80.66% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently weighed in on the stock. Piper Sandler raised their target price on shares of CVS Health from $93.00 to $94.00 and gave the company an “overweight” rating in a research note on Friday, March 15th. StockNews.com lowered shares of CVS Health from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. Barclays initiated coverage on shares of CVS Health in a report on Wednesday, March 6th. They set an “equal weight” rating and a $78.00 price objective for the company. Finally, SVB Leerink began coverage on shares of CVS Health in a research report on Monday, February 26th. They issued an “outperform” rating and a $88.00 price target for the company. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $89.44.
Insiders Place Their Bets
In other CVS Health news, EVP Prem S. Shah sold 29,473 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $76.95, for a total value of $2,267,947.35. Following the transaction, the executive vice president now directly owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.24% of the stock is owned by corporate insiders.
CVS Health Trading Down 1.6 %
NYSE CVS opened at $68.50 on Wednesday. CVS Health Co. has a one year low of $64.41 and a one year high of $83.25. The firm has a 50 day simple moving average of $74.97 and a 200-day simple moving average of $73.76. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.86. The firm has a market cap of $86.34 billion, a price-to-earnings ratio of 10.60, a PEG ratio of 0.92 and a beta of 0.52.
CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.01 by $0.11. CVS Health had a net margin of 2.33% and a return on equity of 15.25%. The company had revenue of $93.81 billion during the quarter, compared to the consensus estimate of $90.58 billion. During the same quarter in the previous year, the firm earned $1.99 earnings per share. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. Equities research analysts anticipate that CVS Health Co. will post 8.31 EPS for the current fiscal year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be issued a dividend of $0.665 per share. The ex-dividend date of this dividend is Friday, April 19th. This represents a $2.66 dividend on an annualized basis and a yield of 3.88%. CVS Health’s payout ratio is currently 41.18%.
CVS Health Company Profile
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Recommended Stories
- Five stocks we like better than CVS Health
- Russell 2000 Index, How Investors Use it For Profitable Trading
- 3 Technologies to Challenge NAND Flash Dominance in AI
- What is a Stock Market Index and How Do You Use Them?
- Is Zoom Video Stock Getting Too Cheap to Pass Up?
- Election Stocks: How Elections Affect the Stock Market
- Packaging Corporation of America: Buy The Dip
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.